Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 19/20 | 0.42 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2805530 | 0.94 | MAPT (0.46) | LMNAMAPTTSHRNPSR1ENPP2 | |
| SCHEMBL2806745 | 0.91 | MAPT (0.45) | LMNAMAPTTSHRNPSR1 | |
| SCHEMBL2810311 | 0.91 | MAPT (0.42) | LMNAMAPTTSHRNPSR1 | |
| SCHEMBL2811498 | 0.91 | MAPT (0.42) | LMNAMAPTTSHRNPSR1 | |
| SCHEMBL2810678 | 0.89 | ENPP2 (0.40) | LMNAMAPTTSHRNPSR1ENPP2 | |
| SCHEMBL2810120 | 0.89 | MAPT (0.38) | LMNAMAPTTSHRNPSR1 | |
| SCHEMBL2809858 | 0.88 | ENPP2 (0.43) | LMNAMAPTTSHRNPSR1ENPP2 | |
| SCHEMBL2809795 | 0.87 | MAPT (0.35) | LMNAMAPTTSHRNPSR1ENPP2 | |
| SCHEMBL16927718 | 0.84 | CLK1 (0.40) | MAPTKCNH2 | |
| SCHEMBL13129753 | 0.84 | NAMPT (0.46) | MAPTTSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2209777-B1 | THIAZOL DERIVATIVES FOR TREATING CANCER | MERCK PATENT GMBH (DE) | 2015-07-29 | — | — | EP | claimed |
| US-8557824-B2 | Thiazole derivatives | MERCK PATENT GMBH (DE) | 2013-10-15 | — | — | US | claimed |
| US-20100240676-A1 | THIAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240676-A1 | THIAZOLE DERIVATIVES | CCNE2, PKD1, PKD2 | LMNA 1974/4885MAPT 1450/4885TSHR 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.